BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 37460928)

  • 1. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    Res Sq; 2023 Feb; ():. PubMed ID: 36865331
    [No Abstract]   [Full Text] [Related]  

  • 3. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.
    Andrikopoulou A; Zografos E; Apostolidou K; Kyriazoglou A; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Liontos M; Dimopoulos MA; Zagouri F
    Front Oncol; 2022; 12():1030786. PubMed ID: 36531003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
    J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
    Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
    Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
    Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent RB1 loss and
    Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Blake Gilks C; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; ; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Rinda Soong T; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
    medRxiv; 2023 Nov; ():. PubMed ID: 37986741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
    Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
    PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1/2 variants and copy number alterations status in non familial triple negative breast cancer and high grade serous ovarian cancer.
    El Ansari FZ; Jouali F; Fekkak R; Bakkach J; Ghailani Nourouti N; Barakat A; Bennani Mechita M; Fekkak J
    Hered Cancer Clin Pract; 2022 Aug; 20(1):29. PubMed ID: 35986351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    Ann Transl Med; 2021 Mar; 9(5):364. PubMed ID: 33842585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
    Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
    J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
    J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
    Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
    BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.